http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
항암제 치료에 있어서 영상 생체표지자로서의 초음파 조영제 영상검사: 파크리탁셀과 이종이식 종양 모델을 이용한 예비연구
이학종,황성일,변종회,공훈영,정현숙,강미라 대한초음파의학회 2011 ULTRASONOGRAPHY Vol.30 No.2
Purpose: We wanted to assess tumor angiogenesis of human prostate cancer cells (PC3) implanted in mice before and after paclitaxel injection via contrast-enhanced ultrasonography (CEUS). Materials and Methods: Twelve mice were injected with human prostate cancer cells (PC3) on the back or hind limbs. The mice were grouped into two groups; one was the paclitaxel treated group (n = 6) and the other was the control group, which was treated with normal saline (n = 6). Before injection of paclitaxel into the peritoneal cavity, baseline CEUS was performed by the administration of 500 μl (1×108microbubbles) of contrast agent. The area under the curve (AUC) up to 50 seconds after contrast injection was derived from the time-intensity curves. After injection of paclitaxel or saline, one week follow up CEUS studies were performed. The changes of the tumor volume and the AUC in both two groups were evaluated. After CEUS, the mice were sacrificed and the microvessel density (MVD) was compared. Results: In the paclitaxel treated group, the AUC from CEUS showed a significant decrease one week after paclitaxel administration (p = 0.03), even though the tumor volume showed no significant changes (p = 0.116). In the control group, there was no significant decrease of the AUC (p = 0.173). Pathologically, there was a significant difference of microvessel density in both groups (p = 0.002). Conclusion: The AUC from the time intensity curve derived from CEUS showed early change in response to the anti-cancer drug treatment in advance of a tumor size response. The findings of CEUS could be an imaging biomarker for assessing the tumor response to anti-cancer drug treatment.
이학종 대한의사협회 2015 대한의사협회지 Vol.58 No.1
The clinical significance of prostate cancer is increasing markedly with an increased population of aged persons and Westernized behavior patterns. Accordingly, the role of prostate imaging is also becoming important in the early diagnosis of prostate cancer. Transrectal prostate ultrasound (TRUS) is used for the estimation of prostate volume as well as the detection of prostate cancer, seen as focal hypoechoic lesions. Almost all prostate tissue biopsies are performed under the guidance of TRUS. One of the important issues in prostate imaging is the visualization of suspected prostate cancer lesions. In order to obtain detailed information regarding a suspected prostate lesion, contrast-enhanced imaging is utilized, using microbubbles and elastography. In addition, magnetic resonance imaging-ultra sonography (MRI-US) fusion imaging, in which the ultrasound machine archives magnetic resonance (MR) images and facilitates MRI-US fusion imaging-guided biopsy, has been revealed to be superior to conventional ultrasound-guided biopsy. Prostate MR is usually performed in patients with confirmed prostate cancer, after prostate biopsy for the evaluation of tumor staging or follow-up changes after chemotherapy, hormone therapy, or radiation therapy. In particular, the evaluation of seminal vesicles is crucial for accurate identification of tumor staging. Advanced functional MR techniques, including diffusion-weighted imaging, dynamic contrast-enhanced imaging, and MR spectroscopy, also have potential in the localization of prostate cancer. In summary, the role of prostate imaging in the diagnosis and localization of prostate cancer is increasing. Advanced technologies in ultrasound and MR imaging may have important roles in localization of prostate cancer and image-guided biopsy.
이학종,황성일,변종회,공훈영,정현숙,강미라 대한초음파의학회 2017 ULTRASONOGRAPHY Vol.36 No.4
Purpose: The purpose of this study was to assess tumor angiogenesis using contrast-enhanced ultrasonography (CEUS) of human prostate cancer cells (PC3) that were implanted in mice before and after paclitaxel injection. Methods: Twelve mice were injected with human PC3. The mice were grouped into two groups; one was the paclitaxel-treated group (n=6) and the other was the control group (n=6). Before administering paclitaxel into the peritoneal cavity, baseline CEUS was performed after the administration of 500 μL (1×108 microbubbles) of contrast agent. The area under the curve (AUC) up to 50 seconds after injection was derived from the time-intensity curves. After injection of paclitaxel or saline, CEUS studies were performed at the 1-week follow-up. Changes in tumor volume and the AUC in both two groups were evaluated. After CEUS, the microvessel density (MVD) was compared between the groups. Results: In the paclitaxel-treated group, the AUC from CEUS showed a significant decrease 1-week after paclitaxel administration (P=0.030), even though the tumor volume showed no significant changes (P=0.116). In the control group, there was no significant decrease of the AUC (P=0.173). Pathologically, there was a significant difference in MVD between both groups (P=0.002). Conclusion: The AUC from the time intensity curve derived from CEUS showed an early change in response to the anti-cancer drug treatment that preceded the change in tumor size. The findings of CEUS could serve as an imaging biomarker for assessing tumor responses to anti-cancer drug treatment.